OR WAIT 15 SECS
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.
Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships.
Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships to bring drugs with enhanced stability and bioactivity to market.
from BioPharm International’s 2013 Innovation Updates and Strategies eBook.
Related Content:
Formulation | Drug Delivery | Formulation and Drug Delivery, Combination Drugs | Development